Search Results

, tackling inequities in access and quality of care for patients with multiple myeloma, and preventing and managing blood clots. Speakers also shared information and research pertaining to the treatment of adult acute lymphoblastic leukemia, acute myeloid

-Acquired Resistance in the Brain and Histologic Transformation in the Lung Expiration Date: 9/19/14 NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 2.2013 Expiration Date: 9/19/14 Controversies in the Treatment of Elderly Patients With Newly

neoplasms. 13 – 34 We now have strong evidence to support molecular testing in patients with various types of cancer, including lung carcinoma, melanoma, colorectal carcinoma, and acute myeloid leukemia, as part of routine clinical practice and standard of

cancers and acute myeloid leukemia. The report grew out of the discussion held by the group in May 2011, when NCCN assembled the task force, comprising oncologists and pathologists from the NCCN Member Institutions and expert participants from the NCI and

elevated in myelodysplastic syndromes and in acute myeloid leukemia . J Hematother Stem Cell Res. 2002 ; 11 : 119 – 125 . 69 Aguayo A Kantarjian H Manshouri T . Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

T he treatment of acute myeloid leukemia (AML) in older patients remains challenging. 1 Both disease- and patient-related factors unfavorably influence patient outcome, with a 2-year probability of overall survival of 10% to 15%. 2 Acute

focused on the evolution of lower- and higher-risk MDS into more aggressive forms of either MDS or acute myeloid leukemia (AML), and has necessitated a clearer description of how these drugs are being used across the country. MDS Epidemiology

1 Bow EJ Loewen R Cheang MS . Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults . J Clin Oncol 1997 ; 15 : 2254 – 2261 . 2 Pfaller MA

many types of cancer, including CLL, acute myeloid leukemia, and CML. 4 , 19 – 27 Venetoclax is now an established therapeutic option in CLL, for use as first-line therapy or in relapsed/refractory disease. 3 , 4 , 28 – 30 This report presents a case

aggressive (acute myeloid leukemia [AML]). Clinical and biological complexity has become apparent in this spectrum of disorders. To help to more clearly define the clinical status, prognosis, and therapeutic strategies for these patients, several clinical